title: The Frontier stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesions.
abstract: OBJECTIVE
  The goal of this study was to evaluate the safety and performance of the Multi-Link Frontier coronary bifurcation stent system (Guidant Corp., Santa Clara, California), a novel dedicated device designed for permanent side branch (SB) access, stent delivery by simultaneous kissing balloon inflation, and optimal main branch (MB) and SB ostium scaffolding.
  
  
  BACKGROUND
  The treatment of coronary bifurcation lesions remains challenging, and various approaches using stents have been proposed.
  
  
  METHODS
  The primary end point was the 180-day incidence of major adverse cardiac events (MACE) per intent-to-treat analysis. Secondary end points included device success, 30-day MACE, angiographic restenosis, and target lesion revascularization (TLR) rates at 180 days.
  
  
  RESULTS
  After a learning phase of two cases per center, 105 patients were prospectively included in 11 centers. The left anterior descending coronary artery/diagonal bifurcation was the target in 80% of cases. The Frontier stent was successfully implanted in 96 patients (91%), and procedural success was obtained in 93%. Two patients suffered in-hospital myocardial infarction (MI) secondary to SB occlusion, and one patient underwent elective coronary artery bypass grafting. At 30 days and 6 months, the MACE rates were 2.9% and 17.1% (no death, no subacute stent thrombosis, Q-wave MI 1.0% and 1.9%, non-Q-wave MI 1.0% and 1.9%, TLR 1.0% and 13.3%). The MB in-stent restenosis was 25.3%, in-segment 29.9%. The SB restenosis was 29.1%. The overall restenosis rate for any branch was 44.8%.
  
  
  CONCLUSIONS
  The results of this Frontier registry demonstrate the safety and performance of this dedicated stent system for the treatment of bifurcation lesions. The device can be successfully implanted in more than 90% of all cases, with a high procedural success rate and low 30-day and 6-month MACE rates.
authors.affiliation: Institut Hospitalier Jacques Cartier, Massy, France. t.lefevre@icps.com.fr
authors.forename: Thierry
authors.initials: T
authors.lastname: Lefèvre
authors.forename: John
authors.initials: J
authors.lastname: Ormiston
authors.forename: Giulio
authors.initials: G
authors.lastname: Guagliumi
authors.forename: Heinz-Peter
authors.initials: HP
authors.lastname: Schultheiss
authors.forename: Laurent
authors.initials: L
authors.lastname: Quilliet
authors.forename: Bernhard
authors.initials: B
authors.lastname: Reimers
authors.forename: Philippe
authors.initials: P
authors.lastname: Brunel
authors.forename: Williams
authors.initials: W
authors.lastname: Wijns
authors.forename: H J
authors.initials: HJ
authors.lastname: Buettner
authors.forename: F
authors.initials: F
authors.lastname: Hartmann
authors.forename: Susan
authors.initials: S
authors.lastname: Veldhof
authors.forename: Karin
authors.initials: K
authors.lastname: Miquel
authors.forename: Xiaolu
authors.initials: X
authors.lastname: Su
authors.forename: Willem J
authors.initials: WJ
authors.lastname: van der Giessen
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation* / Q000379:methods; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation* / Q000379:methods; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000628:therapy; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000628:therapy*; D018450:Disease Progression; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012042:Registries; D012449:Safety; D015607:Stents / Q000009:adverse effects*; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome